CANADA LIFE ASSURANCE Co decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,807 shares of the company's stock after selling 1,393 shares during the period. CANADA LIFE ASSURANCE Co owned about 0.07% of Medpace worth $6,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock valued at $854,087,000 after purchasing an additional 25,704 shares during the period. Invesco Ltd. grew its stake in shares of Medpace by 91.8% during the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after acquiring an additional 519,186 shares during the period. Wasatch Advisors LP increased its holdings in Medpace by 3.1% in the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock worth $311,247,000 after acquiring an additional 28,161 shares in the last quarter. Geode Capital Management LLC raised its stake in Medpace by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after acquiring an additional 28,076 shares during the period. Finally, Bessemer Group Inc. lifted its holdings in Medpace by 15.0% during the fourth quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock valued at $191,379,000 after purchasing an additional 75,275 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Trading Down 2.3 %
Medpace stock opened at $282.28 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The firm has a 50-day moving average price of $316.36 and a 200-day moving average price of $332.53. The firm has a market capitalization of $8.53 billion, a PE ratio of 22.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. Medpace had a return on equity of 51.48% and a net margin of 19.17%. The business had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. During the same quarter in the previous year, the business earned $3.20 earnings per share. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently issued reports on MEDP shares. William Blair reissued a "market perform" rating on shares of Medpace in a research note on Tuesday. Mizuho lowered their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Truist Financial cut their target price on Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target on the stock. Finally, Leerink Partnrs raised shares of Medpace to a "hold" rating in a report on Monday, March 24th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $357.50.
View Our Latest Research Report on MEDP
About Medpace
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
